Comparing QL1206 with Prolia® for postmenopausal osteoporosis with high fracture risk

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind Phase 3 trial comparing the investigational product QL1206 with Prolia® (denosumab) in postmenopausal women aged 50–85 who have osteoporosis and are at high risk for fracture. Eligible participants have a lumbar or total hip BMD T-score ≤ -2.5 and > -4.0 and must have at least one additional fracture risk factor. Participants will be randomly assigned to receive either QL1206 or Prolia® and followed for clinical safety and bone outcomes including changes in bone mineral density and adverse events. The goal is to determine if QL1206 provides comparable efficacy and safety to the established denosumab treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects who agree to participate in the study and sign the informed consent form.
* Postmenopausal women who can walk freely, aged 50-85 years (including 50 and 85 years old).
* Subjects whose absolute value of bone mineral density (BMD) in the lumbar or total hip area meets T values ≤ -2.5 and \> -4.0.
* Subjects who must have at least one of the following risk factors: History of previous fragility fractures (occurring after the age of 40); history of hip fractures in fathers or mothers; increased bone turnover rate during screening; low body weight (BMI ≤ 19 kg/m2); advanced age (aged ≥ 65 years); current smoke.
* The duration of spontaneous amenorrhea was \>2 years or \>2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels \>40mIU/mL may be used to confirm the status of postoperative menopause.

Exclusion Criteria:

* Bone/metabolic disease.
* Hyperparathyroidism or hypoparathyroidism.
* Thyroid condition: Hyperthyroidism or hypothyroidism.
* Rheumatoid arthritis.
* Malabsorption syndrome.
* Renal disease - severe impairment of kidney function.
* Vitamin D defViciency (25-hydroxyvitamin D, 25OHD \<20 ng/mL).
* Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery.
* Previously used denosumab drugs.
* Use of intravenous bisphosphonates, fluoride, or strontium to treat osteoporosis within the last 5 years.
* OOral bisphosphonates (used for at least 3 years, or used for less than 3 years but more than 3 months, with the last use occurring \<1 year before the ICF).
* Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism.
* History of more than two vertebral fractures.
* Malignant tumors.

Where it's running

• Zhejiang Provincial People's Hospital Bijie Hospital
  Guizhou, China Recruiting

Study contacts

• Study coordinator: Youjia Xu
• Email: sdfeyec@163.com
• Phone: +86-0512-67783682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer

  This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT07802821

• First-in-human test of QLS2319 in healthy adults and cancer cachexia

  This study tests QLS2319 in healthy adults and people with cancer cachexia to see if it is safe, tolerated, and how it behaves in the body, with a look at early signs of benefit.

  Recruiting Phase 1/2 Qilu Pharmaceutical Co., Ltd. · Hefei, Anhui and 1 other locations · NCT07735104

• G-CSF–fusion protein to prevent chemotherapy neutropenia in children with sarcoma

  This trial tests Albipagrastim alfa (QLC2519) in children with sarcoma to see if it helps prevent chemotherapy-induced neutropenia.

  Recruiting Phase 2 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07724756

• QLS31905 plus CAPOX vs sintilimab plus CAPOX as first-line treatment for gastric/GEJ cancer

  This phase 3 trial tests whether QLS31905 with CAPOX works as well as or better than sintilimab with CAPOX for first-line treatment in CLDN18.2-positive, PD-L1 CPS < 5, HER2-negative unresectable or metastatic gastric/GEJ cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07716449

• QLC5508 in Advanced Solid Tumors: Formulations, QTc, PK, and Drug-Drug Interactions

  This study tests whether QLC5508 can be safely given to adults with advanced solid tumors and whether two formulations differ in the body, as well as if other drugs change how QLC5508 is processed.

  Recruiting Phase 1 Qilu Pharmaceutical Co., Ltd. · Changchun, Jilin · NCT07620041

• QLS5212 in people with advanced solid tumors

  This early-phase study tests different doses and schedules of QLS5212 given through IV in adults with unresectable or metastatic solid tumors to see if it is safe and tolerable.

  Recruiting Phase 1 Qilu Pharmaceutical Co., Ltd. · Taiyuan · NCT07467629

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.